BeaconEquity.com announces the publication of an article covering recent news from MAP Pharmaceuticals (Nasdaq: MAPP), including MAP’s stock surging on news that its migraine drug Levadex passed its phase III clinical trial, giving the drug a 90% chance of FDA approval.
Investors can view all of the investment articles for free by visiting: http://www.beaconequity.com/m
In the article the author writes:
“After jumping $5.85, or 186%, on Tuesday, and $3.93, or 43.67% yesterday, shares of Map Pharmaceuticals surged nearly 6% to $12.85 this morning, fueled by word of its migraine treatment, Levadex.”
MAP’s migraine drug Levadex has a 90% chance of being approved, according to Investopedia's research:
“Phase III trial results released Tuesday showed the company’s Cinderella drug was suited for the prince, looking exceptionally enticing following statistical proof of the drug’s effectiveness without atypical side-effects associated with Triptans. Phase III represents a big hurdle, with approximately three out of five drugs applied through the U.S. Food and Drug Administration (FDA) making it through this expensive phase, according to the Canadian Medical Association. … Passing Phase III is certainly a milestone, as 90% of drugs graduating through the FDA's basic training stage usually make it to market, according to Investopedia's research.”
To read the entire article visit http://www.beaconequity.com/m
Join the fastest growing investor community at: http://www.stockhideout.com/
BeaconEquity.com’s market news is one of the fastest growing small-cap blogs in the investment community. Beacon is the authority on research in the small-cap sector, and our analysts strive each day to find the stocks poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas.
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.beaconequity.com/m
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
